AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20070811 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative and quantitative data
Number of subjects: 168
Study 20070811 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic reviews, randomized control trials, and quasi-experimental design studies
Number of subjects: 168
Study 20070811 — intervention group
Group type: EXPERIMENTAL
Intervention: All papers
Number of subjects: 168
Study 18097903 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstetric fistulae treatment
Number of subjects: 160
Study 15800937 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine (up to 200 mg daily)
Number of subjects: 31
Study 15800937 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 12450694 — intervention group
Group type: EXPERIMENTAL
Intervention: Urease (60 mg) + LT (5 microg)
Number of subjects: 18
Study 12450694 — intervention group
Group type: EXPERIMENTAL
Intervention: Urease (60 mg) + LT (25 microg)
Number of subjects: 18
Study 12450694 — intervention group
Group type: COMPARATOR
Intervention: Urease (60 mg)
Number of subjects: 18
Study 9558681 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration piezoelectric‐controlled VVIR Sensolog III Siemens pacemaker
Number of subjects: 23
Study 9558681 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerometer‐controlled VVIR Dash Intermedics pacemaker
Number of subjects: 23
Study 9558681 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 23
Study 7617424 — intervention group
Group type: EXPERIMENTAL
Intervention: Pinhole viewing of real ridges
Number of subjects: 0
Study 7617424 — intervention group
Group type: COMPARATOR
Intervention: Control conditions (non-pinhole viewing) for real ridges
Number of subjects: 0
Study 7617424 — intervention group
Group type: EXPERIMENTAL
Intervention: Pinhole viewing of stereograms
Number of subjects: 0
Study 7617424 — intervention group
Group type: COMPARATOR
Intervention: Control conditions for stereograms
Number of subjects: 0
Study 2144154 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg per day
Number of subjects: 435
Study 2144154 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 435
Study 366085 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine (30 mg per day in divided doses)
Number of subjects: 11
Study 366085 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 366085 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 11
Study 31894995 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy (MET)
Number of subjects: 242
Study 31894995 — intervention group
Group type: COMPARATOR
Intervention: Educational control condition
Number of subjects: 242
Study 30909157 — intervention group
Group type: EXPERIMENTAL
Intervention: myPlaybook (web-based alcohol intervention)
Number of subjects: 2449
Study 30909157 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 2449
Study 27880079 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous erythromycin (3 mg/kg)
Number of subjects: 30
Study 27880079 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral erythromycin
Number of subjects: 30
Study 27880079 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 27880079 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline gastric emptying
Number of subjects: 30
Study 27880079 — intervention group
Group type: EXPERIMENTAL
Intervention: Faster gastric emptying
Number of subjects: 30
Study 27880079 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed gastric emptying
Number of subjects: 30
Study 22234829 — intervention group
Group type: EXPERIMENTAL
Intervention: ORT and domperidone
Number of subjects: 56
Study 22234829 — intervention group
Group type: COMPARATOR
Intervention: ORT alone
Number of subjects: 56
Study 23615650 — intervention group
Group type: EXPERIMENTAL
Intervention: Watermelon supplementation (L‐citrulline/L‐arginine 6 g/d)
Number of subjects: 12
Study 21492159 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-probability/high-payout lottery
Number of subjects: 3
Study 21492159 — intervention group
Group type: EXPERIMENTAL
Intervention: High-probability/low-payout lottery
Number of subjects: 3
Study 21492159 — intervention group
Group type: EXPERIMENTAL
Intervention: Unconditional fixed payment
Number of subjects: 3
Study 21492159 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditional fixed payment
Number of subjects: 3
Study 21492159 — intervention group
Group type: COMPARATOR
Intervention: Moderate-probability/moderate-payout lottery
Number of subjects: 3
Study 20077977 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi (intervention not specified in dosage or duration)
Number of subjects: 0
Study 20077977 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi
Number of subjects: 0
Study 17130197 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg once-daily
Number of subjects: 701
Study 17130197 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 701
Study 12601628 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone treatment in Group A
Number of subjects: 87
Study 12601628 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment in Group B
Number of subjects: 87
Study 12601628 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone treatment in Groups B and C
Number of subjects: 87
Study 12601628 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone treatment in all groups
Number of subjects: 87
Study 10553828 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg (2 mL 1.5%)
Number of subjects: 75
Study 10553828 — intervention group
Group type: EXPERIMENTAL
Intervention: 45 mg (3 mL 1.5%)
Number of subjects: 75
Study 10553828 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg (4 mL 1.5%)
Number of subjects: 75
Study 10553828 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall incidence of TNS
Number of subjects: 75
Study 8921789 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanreotide
Number of subjects: 553
Study 8921789 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 553
Study 1759534 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) therapy
Number of subjects: 13
Study 7074797 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (B1)
Number of subjects: 258
Study 7074797 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise and teaching-counseling group (B2)
Number of subjects: 258
Study 7074797 — intervention group
Group type: COMPARATOR
Intervention: Routine medical care (Control group A)
Number of subjects: 258
Study 7074797 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups combined
Number of subjects: 258
Study 30457668 — intervention group
Group type: EXPERIMENTAL
Intervention: Citicoline (titrated to 2,000 mg/d)
Number of subjects: 62
Study 30457668 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 29132478 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal clindamycin (multiple doses)
Number of subjects: 100
Study 29132478 — intervention group
Group type: COMPARATOR
Intervention: Oral secnidazole (single 2-gm dose)
Number of subjects: 100
Study 26419215 — intervention group
Group type: EXPERIMENTAL
Intervention: Positioning in neutral
Number of subjects: 218
Study 26419215 — intervention group
Group type: COMPARATOR
Intervention: Conventional positioning
Number of subjects: 218
Study 24511726 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary education program in self-care
Number of subjects: 60
Study 24511726 — intervention group
Group type: COMPARATOR
Intervention: Normal care program (Control)
Number of subjects: 60
Study 21554817 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-grain wheat (48 g daily for 3 weeks)
Number of subjects: 14
Study 21554817 — intervention group
Group type: COMPARATOR
Intervention: Refined grain (control)
Number of subjects: 14
Study 19231157 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate nephrectomy
Number of subjects: 426
Study 19231157 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy
Number of subjects: 426
Study 16580390 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestrinone
Number of subjects: 135
Study 16580390 — intervention group
Group type: COMPARATOR
Intervention: Danazol
Number of subjects: 135
Study 14714091 — intervention group
Group type: EXPERIMENTAL
Intervention: GSTM1, GSTT1, and GSTP1 genotypes
Number of subjects: 0
Study 14714091 — intervention group
Group type: COMPARATOR
Intervention: Healthy children
Number of subjects: 0
Study 10685531 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (100 mg/d) on days 3-7 of the CC-treated cycles
Number of subjects: 30
Study 10685531 — intervention group
Group type: COMPARATOR
Intervention: Control cycle (no treatment)
Number of subjects: 30
Study 9692707 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg daily; n = 8)
Number of subjects: 24
Study 9692707 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (300 mg b.d.; n = 6)
Number of subjects: 24
Study 9692707 — intervention group
Group type: COMPARATOR
Intervention: Control group (before treatment; n = 24)
Number of subjects: 24
Study 8151082 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoplasia of the corpus callosum
Number of subjects: 445
Study 8151082 — intervention group
Group type: COMPARATOR
Intervention: Control group (63 randomly selected individuals)
Number of subjects: 445
Study 2826067 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalaprilat
Number of subjects: 0
Study 2826067 — intervention group
Group type: COMPARATOR
Intervention: Saline vehicle
Number of subjects: 0
Study 30392805 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited Bursectomy (LB)
Number of subjects: 75
Study 30392805 — intervention group
Group type: COMPARATOR
Intervention: Extensive Bursectomy (EB)
Number of subjects: 75
Study 30392805 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (LB and EB)
Number of subjects: 75
Study 27710149 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxia (2000m above sea level)
Number of subjects: 12
Study 27710149 — intervention group
Group type: COMPARATOR
Intervention: Normoxia (sea level)
Number of subjects: 12
Study 25760389 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% glycolic plant extract applied externally (gel cream) for 21 days
Number of subjects: 8
Study 25760389 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no active treatment)
Number of subjects: 8
Study 23803886 — intervention group
Group type: EXPERIMENTAL
Intervention: β‐carotene supplementation
Number of subjects: 200
Study 20099236 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed combination latanoprost-timolol (n = 170)
Number of subjects: 500
Study 20099236 — intervention group
Group type: COMPARATOR
Intervention: Latanoprost monotherapy (n = 165)
Number of subjects: 500
Study 20099236 — intervention group
Group type: COMPARATOR
Intervention: Timolol monotherapy (n = 165)
Number of subjects: 500
Study 18402906 — intervention group
Group type: EXPERIMENTAL
Intervention: SR123781A 0.25 mg
Number of subjects: 1023
Study 18402906 — intervention group
Group type: EXPERIMENTAL
Intervention: SR123781A 0.5 mg
Number of subjects: 1023
Study 18402906 — intervention group
Group type: EXPERIMENTAL
Intervention: SR123781A 1.0 mg
Number of subjects: 1023
Study 18402906 — intervention group
Group type: EXPERIMENTAL
Intervention: SR123781A 2.0 mg
Number of subjects: 1023
Study 18402906 — intervention group
Group type: EXPERIMENTAL
Intervention: SR123781A 4.0 mg
Number of subjects: 1023
Study 18402906 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin 40 mg (calibrator arm)
Number of subjects: 1023
Study 16376979 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates classes for 4 weeks, 1 hour per day, 5 days a week.
Number of subjects: 30
Study 16376979 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Pilates intervention).
Number of subjects: 30
Study 12386357 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratubal methotrexate 1 mg/kg
Number of subjects: 65
Study 12386357 — intervention group
Group type: COMPARATOR
Intervention: Linear salpingotomy (Control)
Number of subjects: 65
Study 10458218 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorozole (VOR) 2.5 mg once daily
Number of subjects: 452
Study 10458218 — intervention group
Group type: COMPARATOR
Intervention: Megestrol acetate (MA) 40 mg four times per day
Number of subjects: 452
Study 7605361 — intervention group
Group type: EXPERIMENTAL
Intervention: Kwai garlic powder tablets 300 mg three times daily
Number of subjects: 28
Study 7605361 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 28
Study 2163851 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinorphan
Number of subjects: 9
Study 2163851 — intervention group
Group type: COMPARATOR
Intervention: Retorphan
Number of subjects: 9
Study 350002 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotrel traction and exercises
Number of subjects: 10
Study 350002 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise programme
Number of subjects: 10
Study 350002 — intervention group
Group type: COMPARATOR
Intervention: Cotrel traction
Number of subjects: 10
Study 7119301 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 400 micrograms/day, q.i.d.
Number of subjects: 34
Study 7119301 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 800 micrograms/day, q.i.d.
Number of subjects: 34
Study 7119301 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 1600 micrograms/day, q.i.d.
Number of subjects: 34
Study 7119301 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 400 micrograms/day, b.i.d.
Number of subjects: 34
Study 7119301 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 800 micrograms/day, b.i.d.
Number of subjects: 34
Study 7119301 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 1600 micrograms/day, b.i.d.
Number of subjects: 34
Study 7119301 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (various doses), morning dosing
Number of subjects: 34
Study 7119301 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (various doses), reduced dose frequency
Number of subjects: 34
Study 30877269 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS to the DLPFC
Number of subjects: 20
Study 30877269 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (control)
Number of subjects: 20
Study 29946175 — intervention group
Group type: EXPERIMENTAL
Intervention: Ledipasvir-sofosbuvir regimen (8-12 weeks)
Number of subjects: 847
Study 29946175 — intervention group
Group type: EXPERIMENTAL
Intervention: Teleconsultation program for follow-up
Number of subjects: 847
Study 27060731 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated theory-based intervention (outcome mental simulation: present vs. absent; action planning: standard vs. reasoning vs. absent)
Number of subjects: 316
Study 27060731 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention manipulations (either of the intervention manipulation or combination)
Number of subjects: 316
Study 27060731 — intervention group
Group type: COMPARATOR
Intervention: Control group (participants who did not receive intervention manipulations)
Number of subjects: 316
Study 25526462 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep needling
Number of subjects: 475
Study 25526462 — intervention group
Group type: EXPERIMENTAL
Intervention: Shallow needling
Number of subjects: 475
Study 25526462 — intervention group
Group type: COMPARATOR
Intervention: Lactulose
Number of subjects: 475
Study 22406033 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright white light (∼4200 lux) for 30 min every day
Number of subjects: 54
Study 22406033 — intervention group
Group type: EXPERIMENTAL
Intervention: Dim red light (∼90 lux) for 30 min every day
Number of subjects: 54
Study 22406033 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep hygiene therapy
Number of subjects: 54
Study 22406033 — intervention group
Group type: EXPERIMENTAL
Intervention: Phototherapy regimen
Number of subjects: 54
Study 22406033 — intervention group
Group type: COMPARATOR
Intervention: Actigraphy measures
Number of subjects: 54
Study 19170451 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisystemic therapy (MST)
Number of subjects: 48
Study 19170451 — intervention group
Group type: COMPARATOR
Intervention: Usual community services (UCS)
Number of subjects: 48
Study 17947598 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral nutrition (0.2 g/kg/d of nitrogen and 30 nonprotein kcal/kg/d)
Number of subjects: 20
Study 17947598 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral nutrition
Number of subjects: 20
Study 17947598 — intervention group
Group type: COMPARATOR
Intervention: Standard hospital oral diet (control group)
Number of subjects: 20
Study 15939923 — intervention group
Group type: COMPARATOR
Intervention: Fluorouracil (FU) 2.6 g/m(2) and folinic acid (FA) 500 mg/m(2) weekly for 6 weeks followed by a 2-week rest (AIO arm, n = 216)
Number of subjects: 430
Study 15939923 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorouracil (FU) 2.3 or 2.0 g/m(2) preceded by irinotecan 80 mg/m(2) administered over 30 minutes weekly for 6 weeks followed by a 2-week rest (experimental group, n = 214)
Number of subjects: 430
Study 12439209 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose nevirapine (NVP)
Number of subjects: 86
Study 12439209 — intervention group
Group type: COMPARATOR
Intervention: Short-course zidovudine (AZT)
Number of subjects: 86
Study 10456819 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-injection paravertebral block at the level of T4
Number of subjects: 86
Study 10456819 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 86
Study 7727812 — intervention group
Group type: EXPERIMENTAL
Intervention: Novacor N120 Left Ventricular Assist System
Number of subjects: 0
Study 2357777 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous potassium chloride (Group I, 44 patients)
Number of subjects: 189
Study 2357777 — intervention group
Group type: COMPARATOR
Intervention: Intravenous saline (Group II, 48 patients)
Number of subjects: 189
Study 2357777 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral potassium chloride capsules (Group III, 50 patients)
Number of subjects: 189
Study 2357777 — intervention group
Group type: COMPARATOR
Intervention: No additional treatment (Group IV, 47 patients)
Number of subjects: 189
Study 26518 — intervention group
Group type: EXPERIMENTAL
Intervention: Proglumide (1200 mg per day for 28 days)
Number of subjects: 30
Study 26518 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine (1200 mg per day for 28 days)
Number of subjects: 30
Study 31568387 — intervention group
Group type: EXPERIMENTAL
Intervention: Plantar flexor strengthening associated with conventional physical therapy treatment
Number of subjects: 30
Study 31568387 — intervention group
Group type: COMPARATOR
Intervention: Control group treatment (gait training, triceps surae muscle stretching, anterior tibial muscle strengthening, and motor sensory training)
Number of subjects: 30
Study 28767002 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief intervention
Number of subjects: 535
Study 28767002 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary intervention
Number of subjects: 535
Study 28767002 — intervention group
Group type: COMPARATOR
Intervention: Control (not explicitly mentioned)
Number of subjects: 535
Study 27044796 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin cream
Number of subjects: 146
Study 27044796 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating gentamicin/mupirocin regimen
Number of subjects: 146
Study 25061882 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion
Number of subjects: 212
Study 25061882 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 212
Study 22283635 — intervention group
Group type: EXPERIMENTAL
Intervention: LFD
Number of subjects: 42
Study 22283635 — intervention group
Group type: EXPERIMENTAL
Intervention: LFD&PRE
Number of subjects: 42
Study 22283635 — intervention group
Group type: EXPERIMENTAL
Intervention: CRD
Number of subjects: 42
Study 22283635 — intervention group
Group type: EXPERIMENTAL
Intervention: CRD&PRE
Number of subjects: 42
Study 19019257 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant stanol or sterol ester (2 g)
Number of subjects: 282
Study 19019257 — intervention group
Group type: COMPARATOR
Intervention: Control spread
Number of subjects: 282
Study 17682990 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc nasal gel
Number of subjects: 14
Study 17682990 — intervention group
Group type: COMPARATOR
Intervention: Zinc lozenges or nasal spray
Number of subjects: 14
Study 16405839 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokines absorption using sulfonated polyacrylonitrile hemofilter (AN69)
Number of subjects: 30
Study 12021824 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 mg caffeine
Number of subjects: 52
Study 12021824 — intervention group
Group type: EXPERIMENTAL
Intervention: 325 mg caffeine
Number of subjects: 52
Study 12021824 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 12021824 — intervention group
Group type: COMPARATOR
Intervention: Placebo-informed instructions
Number of subjects: 52
Study 12021824 — intervention group
Group type: COMPARATOR
Intervention: Placebo-uninformed instructions
Number of subjects: 52
Study 10193919 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergic Rhinitis (AR)
Number of subjects: 45
Study 10193919 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasomotor Rhinitis (VMR)
Number of subjects: 45
Study 10193919 — intervention group
Group type: COMPARATOR
Intervention: Control Group (Healthy Nonallergic Women)
Number of subjects: 45
Study 8533175 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal exercise (twice weekly for three months)
Number of subjects: 20
Study 2080308 — intervention group
Group type: EXPERIMENTAL
Intervention: UDPG (400 mg/im/die for 30 days)
Number of subjects: 40
Study 2080308 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 2080308 — intervention group
Group type: EXPERIMENTAL
Intervention: UDPG
Number of subjects: 40
Study 374446 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (Ritalin)
Number of subjects: 22
Study 374446 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 31751776 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine care model (CoYoT1 Clinic)
Number of subjects: 0